SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines into clinical development, with the company targeting Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. The round was led by Vida Ventures and included major biotech and pharma investors. The company plans to use the financing to progress lead programs and expand its pipeline of targeted redosable genetic medicines. SonoThera’s platform combines an ultrasound-mediated delivery system (RIPPLE) with a payload engineering layer (PORE), aiming to address classic hurdles in gene therapy including delivery, immune responses, and redosing. SonoThera expects its first DMD clinical trial to begin in 2027, giving the market a clearer development cadence for non-viral, ultrasound-assisted delivery approaches.